Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ: VANI )

1.160 -0.020 (-1.69%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,088
Open 1.170
Bid (Size) 1.140 (23)
Ask (Size) 1.160 (2)
Prev. Close 1.180
Today's Range 1.140 - 1.180
52wk Range 1.000 - 7.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology. 
Via Benzinga

Performance

YTD
+11.54%
+11.54%
1 Month
-15.33%
-15.33%
3 Month
-3.33%
-3.33%
6 Month
-9.38%
-9.38%
1 Year
+2.65%
+2.65%

More News

Read More
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024
Via InvestorPlace
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying
Via Benzinga
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Via Benzinga
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why GLP-1 Developer Vivani Medical's Stock Is Climbing
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use
Via Benzinga
Exposures Product Safety
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use
Via Benzinga
VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.